ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

ClinicalTrials.gov ID: NCT00483301

Public ClinicalTrials.gov record NCT00483301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00483301
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Enrollment
34 participants

Conditions and interventions

Interventions

  • ABI-007(Abraxane) Drug
  • Sorafenib (BAY 43-9006) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2007
Primary completion
Jul 31, 2009
Completion
Jul 31, 2009
Last update posted
May 2, 2012

2007 – 2009

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Dr. Steven O'Day Los Angeles California 90025
Mt. Sinai Medical Center Miami Beach Florida 33140

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00483301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2012 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00483301 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →